MRX-502: Randomized double-blind placebo-controlled Phase 3 study to evaluate the efficacy and safety of maralixibat in the treatment of subjects with Progressive Familial Intrahepatic Cholestasis (PFIC) – MARCH-PFIC
MRX-502: Randomized double-blind placebo-controlled Phase 3 study to evaluate the efficacy and safety of maralixibat in the treatment of subjects with Progressive Familial Intrahepatic Cholestasis (PFIC) – MARCH-PFIC